These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

575 related items for PubMed ID: 19528367

  • 1. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment.
    Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT.
    Diabetes Care; 2009 Sep; 32(9):1656-62. PubMed ID: 19528367
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].
    Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S, Studiengruppe Dapagliflozin 006.
    Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S27-38. PubMed ID: 23529568
    [Abstract] [Full Text] [Related]

  • 5. Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial.
    Yang W, Ma J, Li Y, Li Y, Zhou Z, Kim JH, Zhao J, Ptaszynska A.
    J Diabetes; 2018 Jul; 10(7):589-599. PubMed ID: 29215189
    [Abstract] [Full Text] [Related]

  • 6. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
    Henry RR, Rosenstock J, Edelman S, Mudaliar S, Chalamandaris AG, Kasichayanula S, Bogle A, Iqbal N, List J, Griffen SC.
    Diabetes Care; 2015 Mar; 38(3):412-9. PubMed ID: 25271207
    [Abstract] [Full Text] [Related]

  • 7. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C, Ranetti AE, Li D, Ekholm E, Cook W, Hirshberg B, Chen H, Hansen L, Iqbal N.
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [Abstract] [Full Text] [Related]

  • 8. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.
    Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF.
    Diabetes Care; 2010 Oct; 33(10):2217-24. PubMed ID: 20566676
    [Abstract] [Full Text] [Related]

  • 9. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.
    Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF.
    BMC Med; 2013 Feb 20; 11():43. PubMed ID: 23425012
    [Abstract] [Full Text] [Related]

  • 10. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, Jabbour SA.
    Lancet Diabetes Endocrinol; 2016 Dec 20; 4(12):1004-1016. PubMed ID: 27651331
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period.
    Araki E, Onishi Y, Asano M, Kim H, Ekholm E, Johnsson E, Yajima T.
    J Diabetes Investig; 2016 Jul 20; 7(4):555-64. PubMed ID: 27181422
    [Abstract] [Full Text] [Related]

  • 13. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
    Bailey CJ, Gross JL, Pieters A, Bastien A, List JF.
    Lancet; 2010 Jun 26; 375(9733):2223-33. PubMed ID: 20609968
    [Abstract] [Full Text] [Related]

  • 14. Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C.
    Skolnik N, Bonnes H, Yeh H, Katz A.
    Postgrad Med; 2016 May 26; 128(4):356-63. PubMed ID: 27043045
    [Abstract] [Full Text] [Related]

  • 15. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
    Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S, Study 05 Group.
    Diabetes Care; 2015 Mar 26; 38(3):365-72. PubMed ID: 25592197
    [Abstract] [Full Text] [Related]

  • 16. Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.
    Bailey CJ, Iqbal N, T'joen C, List JF.
    Diabetes Obes Metab; 2012 Oct 26; 14(10):951-9. PubMed ID: 22776824
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial.
    Yang W, Han P, Min KW, Wang B, Mansfield T, T'Joen C, Iqbal N, Johnsson E, Ptaszynska A.
    J Diabetes; 2016 Nov 26; 8(6):796-808. PubMed ID: 26589253
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
    Mathieu C, Dandona P, Gillard P, Senior P, Hasslacher C, Araki E, Lind M, Bain SC, Jabbour S, Arya N, Hansen L, Thorén F, Langkilde AM, DEPICT-2 Investigators.
    Diabetes Care; 2018 Sep 26; 41(9):1938-1946. PubMed ID: 30026335
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
    Dharmalingam M, Aravind SR, Thacker H, Paramesh S, Mohan B, Chawla M, Asirvatham A, Goyal R, Shembalkar J, Balamurugan R, Kadam P, Alva H, Kodgule R, Tandon M, Vaidyanathan S, Pendse A, Gaikwad R, Katare S, Suryawanshi S, Barkate H.
    Drugs; 2020 Apr 26; 80(6):587-600. PubMed ID: 32162274
    [Abstract] [Full Text] [Related]

  • 20. Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.
    Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ.
    Diabetes Care; 2015 Jul 26; 38(7):1218-27. PubMed ID: 25852208
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.